RE:Pharmala's US patent granted for ALA-002 The Market cap of this company doesn't make much sense at these prices with their IP and business proceeding in Australia and Canada which hasn't changed when it traded at over 30 cents.
Nick has said time and time again that an FDA approval would have given Lykos exclusivity to the US market for 5 years and so Pharmala's focus is in Europe and South America. And he has said that it can be very expensive to break into the US market with new drugs so it has never been their focus. However, the company can now look at supplying clinical trials in the US market with LaNeo MDMA if they choose to for additional revenue. To an extent this is good news for Pharmala. Lykos' loss is Pharmala's gain.
Again, their focus is moving into the European and South American markets. A much smarter move, which has not changed. Those markets were always on their own path regardless of what the FDA decided in the US. Nick's focus has always been correctly focused on the best markets to enter for the least cost to the company. This comes with his knowledge and experience of understanding regulations. Eventually they will work their way into the US with their new drugs.
ALA-002 intrigues me the most because it could eventually get ophan designation status for increasing social interactions for those with autism spectrum disorder. This type of drug would be the first of its kind and any treatment use may also recieve it own data exclusity period by the FDA as well. interesting times ahead with FDA approved patent now in hand.